Jane Street Group LLC Cuts Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Jane Street Group LLC reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 23.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,976 shares of the specialty pharmaceutical company’s stock after selling 6,287 shares during the period. Jane Street Group LLC owned 0.09% of ANI Pharmaceuticals worth $1,192,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Texas Permanent School Fund Corp grew its holdings in ANI Pharmaceuticals by 1.3% in the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock worth $852,000 after purchasing an additional 178 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in ANI Pharmaceuticals by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after buying an additional 200 shares during the last quarter. Arizona State Retirement System boosted its holdings in ANI Pharmaceuticals by 4.7% in the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after acquiring an additional 211 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares during the last quarter. Finally, New York State Teachers Retirement System increased its holdings in shares of ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after acquiring an additional 394 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $54.41 on Monday. The firm’s fifty day moving average is $57.36 and its two-hundred day moving average is $59.56. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -98.93 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the prior year, the business earned $1.05 earnings per share. The company’s revenue was up 12.5% compared to the same quarter last year. Research analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

Wall Street Analysts Forecast Growth

ANIP has been the topic of several research analyst reports. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective on the stock. Raymond James raised their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Truist Financial increased their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $77.71.

Insider Activity

In related news, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,231 shares of company stock valued at $2,434,286 in the last three months. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.